80690-66-0

Usage

Uses

Used in Organic Synthesis:
BenzenaMine, 4-chloro-3-ethynylis used as an intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows for the formation of new bonds and reactions, making it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, BenzenaMine, 4-chloro-3-ethynylis used as a building block in the development of new drugs. Its chemical properties can be harnessed to create novel drug candidates with potential therapeutic effects. Researchers can modify its structure to explore its potential in treating various diseases and conditions.
Used in Material Science:
BenzenaMine, 4-chloro-3-ethynylmay also have potential applications in the development of new materials. Its unique structure can contribute to the creation of advanced materials with specific properties, such as improved conductivity, stability, or reactivity. This can be particularly useful in industries like electronics, where new materials with enhanced performance are constantly sought after.
It is important to handle BenzenaMine, 4-chloro-3-ethynylwith caution and follow proper safety protocols, as it may pose health and environmental risks if not used and disposed of properly.

Upstream product

• 74534-15-9 1-chloro-2-iodo-4-nitrobenzene 

Relevant academic research and scientific papers

3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF

The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer

Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity. A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were synthesized. In vitro cell-based phenotypic screening together with in vivo assays and structure-activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (13an). 13an is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction. This compound showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity. Mechanisms of action of anti-TNBC were also investigated. Collectively, the data obtained in this study indicate that 13an could be a promising drug candidate for the treatment of TNBC and hence merits further studies.